Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results
Author:
Affiliation:
1. National Institutes of Health, Bethesda, MD
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.66.5364
Reference19 articles.
1. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
2. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
3. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
4. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
5. FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Aberrant Overexpression of Myosin 1b in Glioblastoma Promotes angiogenesis via VEGF-myc-myosin 1b- Piezo1 Axis;2023-08-04
2. Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma;Neuro-Oncology Advances;2023-01-01
3. Human Glioma Endothelial Cells With Stem cell properties;2022-12-28
4. Enhancing selective photosensitizer accumulation and oxygen supply for high-efficacy photodynamic therapy toward glioma by 5-aminolevulinic acid loaded nanoplatform;Journal of Colloid and Interface Science;2020-04
5. Vessel co-option and resistance to anti-angiogenic therapy;Angiogenesis;2019-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3